questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines membranaires
Perforines
Hémolysines
Hémolysines : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hémolysines : Questions médicales les plus fréquentes",
"headline": "Hémolysines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hémolysines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-22",
"dateModified": "2025-04-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hémolysines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Perforines",
"url": "https://questionsmedicales.fr/mesh/D052899",
"about": {
"@type": "MedicalCondition",
"name": "Perforines",
"code": {
"@type": "MedicalCode",
"code": "D052899",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.695"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Hémolysines",
"alternateName": "Hemolysin Proteins",
"code": {
"@type": "MedicalCode",
"code": "D006460",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Vanesa Herlax",
"url": "https://questionsmedicales.fr/author/Vanesa%20Herlax",
"affiliation": {
"@type": "Organization",
"name": "Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP), CCT- La Plata, CONICET. Facultad de Ciencias Médicas. Universidad Nacional de La Plata, Argentina. Electronic address: vherlax@med.unlp.edu.ar."
}
},
{
"@type": "Person",
"name": "Li Li",
"url": "https://questionsmedicales.fr/author/Li%20Li",
"affiliation": {
"@type": "Organization",
"name": "Sichuan Animal Disease Prevention and Control Center, Chengdu 610041, China."
}
},
{
"@type": "Person",
"name": "Lucía Cané",
"url": "https://questionsmedicales.fr/author/Luc%C3%ADa%20Can%C3%A9",
"affiliation": {
"@type": "Organization",
"name": "Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP), CCT- La Plata, CONICET. Facultad de Ciencias Médicas. Universidad Nacional de La Plata, Argentina."
}
},
{
"@type": "Person",
"name": "Pablo J Schwarzbaum",
"url": "https://questionsmedicales.fr/author/Pablo%20J%20Schwarzbaum",
"affiliation": {
"@type": "Organization",
"name": "Instituto de Química y Fisico-Química Biológicas (IQUIFIB) \"Prof. Alejandro C. Paladini\", Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina."
}
},
{
"@type": "Person",
"name": "Lin Wei",
"url": "https://questionsmedicales.fr/author/Lin%20Wei",
"affiliation": {
"@type": "Organization",
"name": "Changchun University of Chinese Medicine, Changchun, 130117, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Associations between detectable circulating tumor DNA and tumor glucose uptake measured by",
"datePublished": "2023-07-11",
"url": "https://questionsmedicales.fr/article/37434111",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12885-023-11147-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Concordance between whole exome sequencing of circulating tumor DNA and tumor tissue.",
"datePublished": "2023-10-25",
"url": "https://questionsmedicales.fr/article/37878600",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0292879"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.",
"datePublished": "2023-06-16",
"url": "https://questionsmedicales.fr/article/37330052",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.annonc.2023.06.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Circulating Tumor DNA in the Management of Early-Stage Breast Cancer.",
"datePublished": "2023-06-07",
"url": "https://questionsmedicales.fr/article/37371043",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cells12121573"
}
},
{
"@type": "ScholarlyArticle",
"name": "Methodology established for the detection of circulating tumor DNA by hybridization capture.",
"datePublished": "2022-09-06",
"url": "https://questionsmedicales.fr/article/36065956",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2144/btn-2022-0029"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Perforines",
"item": "https://questionsmedicales.fr/mesh/D052899"
},
{
"@type": "ListItem",
"position": 6,
"name": "Hémolysines",
"item": "https://questionsmedicales.fr/mesh/D006460"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hémolysines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hémolysines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hémolysines",
"description": "Comment diagnostiquer une infection par hémolysines ?\nQuels tests sont utilisés pour détecter les hémolysines ?\nLes hémolysines sont-elles visibles sur une analyse sanguine ?\nQuels signes indiquent une hémolyse dans le sang ?\nPeut-on détecter les hémolysines par PCR ?",
"url": "https://questionsmedicales.fr/mesh/D006460?mesh_terms=Circulating+Tumor+DNA&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hémolysines",
"description": "Quels sont les symptômes d'une infection hémolytique ?\nComment l'hémolyse affecte-t-elle le corps ?\nY a-t-il des symptômes spécifiques aux hémolysines ?\nLes hémolysines provoquent-elles des réactions allergiques ?\nQuels signes cliniques sont associés à l'hémolyse ?",
"url": "https://questionsmedicales.fr/mesh/D006460?mesh_terms=Circulating+Tumor+DNA&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hémolysines",
"description": "Comment prévenir les infections par hémolysines ?\nLes personnes à risque doivent-elles prendre des précautions ?\nLes hémolysines peuvent-elles être évitées par l'alimentation ?\nLes mesures d'hygiène sont-elles suffisantes ?\nLes voyages à l'étranger augmentent-ils le risque d'hémolyse ?",
"url": "https://questionsmedicales.fr/mesh/D006460?mesh_terms=Circulating+Tumor+DNA&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hémolysines",
"description": "Quel traitement est recommandé pour une infection hémolytique ?\nComment traiter l'anémie causée par hémolyse ?\nLes corticostéroïdes sont-ils efficaces contre l'hémolyse ?\nY a-t-il des traitements préventifs pour les hémolysines ?\nQuand faut-il envisager une splénectomie ?",
"url": "https://questionsmedicales.fr/mesh/D006460?mesh_terms=Circulating+Tumor+DNA&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hémolysines",
"description": "Quelles complications peuvent survenir avec l'hémolyse ?\nL'hémolyse peut-elle entraîner des problèmes rénaux ?\nY a-t-il un risque de choc hypovolémique ?\nLes complications neurologiques sont-elles possibles ?\nComment gérer les complications liées à l'hémolyse ?",
"url": "https://questionsmedicales.fr/mesh/D006460?mesh_terms=Circulating+Tumor+DNA&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hémolysines",
"description": "Quels sont les facteurs de risque d'hémolyse ?\nLes personnes âgées sont-elles plus à risque ?\nLes maladies génétiques augmentent-elles le risque d'hémolyse ?\nLe stress peut-il influencer l'hémolyse ?\nLes transfusions sanguines augmentent-elles le risque d'hémolyse ?",
"url": "https://questionsmedicales.fr/mesh/D006460?mesh_terms=Circulating+Tumor+DNA&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection par hémolysines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic peut être établi par des tests sanguins et cultures bactériennes."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les hémolysines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'hémolyse sur milieux de culture et les tests sérologiques sont courants."
}
},
{
"@type": "Question",
"name": "Les hémolysines sont-elles visibles sur une analyse sanguine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles ne sont pas directement visibles, mais peuvent être détectées par des tests spécifiques."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une hémolyse dans le sang ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation de la bilirubine et une diminution des globules rouges peuvent indiquer une hémolyse."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les hémolysines par PCR ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la PCR peut être utilisée pour détecter les gènes codant pour les hémolysines."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une infection hémolytique ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fièvre, fatigue, et signes d'anémie comme pâleur."
}
},
{
"@type": "Question",
"name": "Comment l'hémolyse affecte-t-elle le corps ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hémolyse peut entraîner une anémie, une jaunisse et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux hémolysines ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs lombaires et des urines foncées peuvent survenir en cas d'hémolyse."
}
},
{
"@type": "Question",
"name": "Les hémolysines provoquent-elles des réactions allergiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent provoquer des réactions immunitaires, mais pas des allergies classiques."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à l'hémolyse ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent tachycardie, hypotension et signes de choc dans les cas graves."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections par hémolysines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir une bonne hygiène et se faire vacciner contre les bactéries responsables."
}
},
{
"@type": "Question",
"name": "Les personnes à risque doivent-elles prendre des précautions ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées doivent éviter les contacts avec des sources d'infection."
}
},
{
"@type": "Question",
"name": "Les hémolysines peuvent-elles être évitées par l'alimentation ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée renforce le système immunitaire, mais ne prévient pas directement."
}
},
{
"@type": "Question",
"name": "Les mesures d'hygiène sont-elles suffisantes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont essentielles, mais doivent être combinées avec la vaccination pour une protection optimale."
}
},
{
"@type": "Question",
"name": "Les voyages à l'étranger augmentent-ils le risque d'hémolyse ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains pays présentent un risque accru d'infections hémolytiques, surtout sans vaccination."
}
},
{
"@type": "Question",
"name": "Quel traitement est recommandé pour une infection hémolytique ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antibiotiques sont souvent prescrits pour traiter les infections causées par hémolysines."
}
},
{
"@type": "Question",
"name": "Comment traiter l'anémie causée par hémolyse ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des transfusions sanguines et des suppléments de fer peuvent être nécessaires."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces contre l'hémolyse ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent réduire l'inflammation et la destruction des globules rouges."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements préventifs pour les hémolysines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination contre certaines bactéries peut aider à prévenir les infections hémolytiques."
}
},
{
"@type": "Question",
"name": "Quand faut-il envisager une splénectomie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une splénectomie peut être envisagée en cas d'hémolyse auto-immune sévère et réfractaire."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'hémolyse ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'anémie sévère, la jaunisse et des défaillances organiques."
}
},
{
"@type": "Question",
"name": "L'hémolyse peut-elle entraîner des problèmes rénaux ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hémolyse peut provoquer une insuffisance rénale aiguë en raison de la libération de toxines."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de choc hypovolémique ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une hémolyse massive peut entraîner un choc hypovolémique en raison de la perte de sang."
}
},
{
"@type": "Question",
"name": "Les complications neurologiques sont-elles possibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques peuvent survenir, notamment en cas d'anémie sévère prolongée."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'hémolyse ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion nécessite un traitement rapide des infections et un suivi médical régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'hémolyse ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des maladies auto-immunes, des infections et des antécédents transfusionnels."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées ont un risque accru d'hémolyse en raison de la fragilité de leur système immunitaire."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque d'hémolyse ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies génétiques, comme la sphérocytose, augmentent le risque d'hémolyse."
}
},
{
"@type": "Question",
"name": "Le stress peut-il influencer l'hémolyse ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut affaiblir le système immunitaire, augmentant ainsi le risque d'infections hémolytiques."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines augmentent-elles le risque d'hémolyse ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des transfusions incompatibles peuvent provoquer une hémolyse aiguë."
}
}
]
}
]
}
The low level of circulating tumor DNA (ctDNA) in the blood is a well-known challenge for the application of liquid biopsies in early-stage non-small cell lung cancer (NSCLC) management. Studies of me...
Patients with stage I-III NSCLC who had routinely undergone an...
In total, 63 patients (median age 70 years, 60% women, and 90% adenocarcinoma) were included. The tumor glucose uptake (SUVmax, MTV, and TLG) was significantly higher in patients with detectable ctDNA...
There was a positive correlation between plasma ctDNA quantity and MTV and TLG in early-stage NSCLC patients. Despite the correlation, the results indicated that ctDNA detection was a negative prognos...
Next generation sequencing of circulating tumor DNA (ctDNA) has been used as a noninvasive alternative for cancer diagnosis and characterization of tumor mutational landscape. However, low ctDNA fract...
The isolation of cell-free DNA (cfDNA) from the bloodstream can be used to detect and analyze somatic alterations in circulating tumor DNA (ctDNA), and multiple cfDNA-targeted sequencing panels are no...
We used machine learning models of fragmentation patterns at the first coding exon in standard targeted cancer gene cfDNA sequencing panels to distinguish between cancer and non-cancer patients, as we...
In the UW cohort, training cross-validated accuracy was 82.1%, and accuracy in the independent validation cohort was 86.6% despite a median ctDNA fraction of only 0.06. In the GRAIL cohort, to assess ...
To our knowledge, this is the first study to demonstrate that sequencing from targeted cfDNA panels can be utilized to analyze fragmentation patterns to classify cancer types, dramatically expanding t...
Liquid biopsies refer to the isolation and analysis of tumor-derived biological material from body fluids, most commonly blood, in order to provide clinically valuable information for the management o...
Roche's AVENIO ctDNA analysis kits and bioinformatics analysis (the AVENIO system) are accessible to all NGS laboratories. We have developed an approach, namely the Sec-Seq system, and compared the ac...
Circulating tumor DNA (ctDNA) has predictive and prognostic value in localized and metastatic cancer. This study analyzed the prognostic value of baseline and on-treatment ctDNA in metastatic gastroes...
Cell free DNA was isolated from plasma of patients before start of first-line palliative systemic treatment and after 9 and 18 weeks. Two NGS panels were designed comprising the most frequently mutate...
ctDNA was detected in pretreatment plasma in 75% of 72 patients and correlated well with mutations in metastatic biopsies (86% accordance). The VAF correlated with baseline tumor volume (Pearson's R 0...
Based on our NGS panel, the number of ctDNA mutations before start of first-line chemotherapy has prognostic value. Moreover, residual ctDNA after three cycles of systemic treatment is associated with...
Gastric cancer is the fifth most common disease in the world and the fourth most common cause of death. It is diagnosed through esophagogastroduodenoscopy with biopsy; however, there are limitations i...
This review aims to explore the role of circulating tumor DNA (ctDNA) as a biomarker for patient selection in breast cancer. We describe the current evidence and the main ongoing trials both in the ea...
In the metastatic setting, the analysis of ctDNA can identify specific genetic alterations amenable of molecularly targeted treatments. Several assays are now approved for the detection of genetic alt...
Liquid biopsy for ctDNA detection represents an exciting new field in rapid evolution. Several trials are ongoing to validate the clinical utility of ctDNA in daily practice in the early setting and t...
Somatic and germline variants are not distinguishable by circulating tumor DNA (ctDNA) testing without analyzing non-tumor samples. Although confirmatory germline testing is clinically relevant, the c...
A total of consecutive 106 patients with advanced solid tumors who underwent ctDNA testing (Guardant360...
Among 223 pathogenic variants reported in ctDNA testing, the median VAF was 0.9% (0.02-81.8%), and 88 variants with ≥ 1% VAFs were analyzed in germline sequencing. Among 25 variants with ≥ 30% VAFs, s...
Our current study demonstrated that VAFs values are helpful for selecting presumed germline variants in clinical ctDNA testing....
The assessment of plasma for circulating tumor DNA (ctDNA) via liquid biopsy has revolutionized our understanding of breast cancer pathogenesis and evolution. Historically, genotyping evaluation of br...